Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir. (3rd November 2022)

• Record Type: Journal Article
• Authors: Ford, Emily S; Simmons, William; Karmarkar, Ellora N; Yoke, Leah H; Braimah, Ayodale B; Orozco, Johnnie J; Ghiuzeli, Cristina M; Barnhill, Serena; Sack, Coralynn L; Benditt, Joshua O; Roychoudhury, Pavitra; Greninger, Alexander L; Shapiro, Adrienne E; Hammond, Jennifer L; Rusnak, James M; Dolsten, Mikael; Boeckh, Michael; Liu, Catherine; Cheng, Guang-Shing; Corey, Lawrence
• Is Part Of: Clinical infectious diseases. Volume 76:Number 5(2023)
• Page Start: 926
• Page End: 929
• Publication Date: 2022-11-03
• Subjects: SARS-CoV-2 -- nirmatrelvir/ritonavir -- severe immunocompromise -- persistent viral infection -- emergency single use investigational new drug; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac868
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: A patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, intravenous (IV) remdesivir and prolonged oral steroids. Twenty days of nirmatrelvir/ritonavir and 10 days of IV remdesivir led to full recovery.